ValiRx (LSE:VAL) EBIT per Share : £-0.03 (TTM As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx EBIT per Share?

ValiRx's EBIT per Share for the six months ended in Jun. 2023 was £-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.03.

During the past 3 years, the average EBIT per Share Growth Rate was 55.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 63.60% per year. During the past 10 years, the average EBIT per Share Growth Rate was 55.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for ValiRx's EBIT per Share or its related term are showing as below:

LSE:VAL' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 1.9 Med: 46.4 Max: 75.1
Current: 55

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of ValiRx was 75.10% per year. The lowest was 1.90% per year. And the median was 46.40% per year.

LSE:VAL's 3-Year EBIT Growth Rate is ranked better than
94.28% of 1311 companies
in the Biotechnology industry
Industry Median: 3.5 vs LSE:VAL: 55.00

ValiRx's EBIT for the six months ended in Jun. 2023 was £-1.15 Mil.

ValiRx EBIT per Share Historical Data

The historical data trend for ValiRx's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx EBIT per Share Chart

ValiRx Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-1.32

-0.38

-0.04

-0.03

ValiRx Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.01	-0.02	-0.02	-0.01

ValiRx EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

ValiRx's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.593	/	77.302
=	-0.03

ValiRx's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

	EBIT per Share		(Q: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.151	/	100.808
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.03

ValiRx (LSE:VAL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

ValiRx EBIT per Share Related Terms

Thank you for viewing the detailed overview of ValiRx's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx (LSE:VAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.